🌐 English में देखें
D
🆓 मुफ्त
🇮🇳 हिंदी
DrugCard
DrugCard क्या है?
DrugCard is a SaaS pharmacovigilance platform purpose-built to automate local and global medical literature screening for Marketing Authorization Holders (MAHs), Contract Research Organizations (CROs), and independent pharmacovigilance consultants. The platform monitors over 1,000 local journals across 55+ countries, supports screening in more than 100 languages, and applies proprietary OCR technology that achieves up to 99% recognition accuracy on poorly scanned texts — a technically critical threshold for journals in lower-income markets where digital formatting standards vary widely.
Manual literature screening is one of the highest-cost recurring compliance obligations in pharmacovigilance. A single drug's GVP-compliant monitoring program across multiple regions can require a specialist to review dozens of local journals per month, translating non-English content and logging adverse event signals that may appear in obscure regional publications. DrugCard replaces this process with automated, auditable screening that records every step in a traceable log ready for regulatory inspection — with FDA 21 CFR Part 11-compliant records and signatures, plus a certificate of conformity for EU, US, and CIS regions, hosted on ISO/IEC 27001:2013 and SOC 2 Type II certified infrastructure. New journals and markets can be integrated within 2–3 weeks of request.
DrugCard is not appropriate for organizations that need a full end-to-end adverse event case management system — it is a screening and monitoring platform, and case processing workflows require integration with a separate safety database such as Argus Safety or Oracle Empirica. Teams looking for open-access systematic review automation for academic literature should evaluate DistillerSR, which is designed for PRISMA-compliant review workflows rather than regulatory pharmacovigilance contexts. A free 2-week trial is available without committing to a subscription.
Manual literature screening is one of the highest-cost recurring compliance obligations in pharmacovigilance. A single drug's GVP-compliant monitoring program across multiple regions can require a specialist to review dozens of local journals per month, translating non-English content and logging adverse event signals that may appear in obscure regional publications. DrugCard replaces this process with automated, auditable screening that records every step in a traceable log ready for regulatory inspection — with FDA 21 CFR Part 11-compliant records and signatures, plus a certificate of conformity for EU, US, and CIS regions, hosted on ISO/IEC 27001:2013 and SOC 2 Type II certified infrastructure. New journals and markets can be integrated within 2–3 weeks of request.
DrugCard is not appropriate for organizations that need a full end-to-end adverse event case management system — it is a screening and monitoring platform, and case processing workflows require integration with a separate safety database such as Argus Safety or Oracle Empirica. Teams looking for open-access systematic review automation for academic literature should evaluate DistillerSR, which is designed for PRISMA-compliant review workflows rather than regulatory pharmacovigilance contexts. A free 2-week trial is available without committing to a subscription.
संक्षेप में
DrugCard is an AI Tool that addresses one of pharmacovigilance's most resource-intensive compliance requirements — local literature monitoring — through automated multilingual screening with full audit traceability. Customer feedback validates 50–70% time savings over manual processes, and the platform's regulatory infrastructure covers FDA, EU, and CIS compliance requirements out of the box. It operates as a focused screening module rather than a complete safety database, requiring integration with case management systems for end-to-end pharmacovigilance workflow coverage.
मुख्य विशेषताएं
AI-Enabled Data Intelligence
DrugCard applies AI algorithms trained specifically on pharmacovigilance terminology to identify adverse drug reaction signals, drug name variants, and safety-relevant content across local and global literature — reducing the false-positive burden that generic keyword-matching systems impose on specialist reviewers who must manually confirm each flagged article.
Multi-Language Support
The platform screens medical literature in over 100 languages, including journals from markets where GVP-compliant local monitoring is legally required but manual screening by language-qualified specialists is cost-prohibitive. Automatic translation is built into the screening pipeline, enabling multilingual coverage without maintaining a roster of language-specialist reviewers.
OCR Technology
DrugCard's proprietary OCR engine achieves up to 99% recognition accuracy on scanned journal content, including poorly digitized regional publications where standard OCR tools fail on degraded images. This technical performance is critical for literature programs that include smaller local journals not available in indexed digital-native formats.
Scalable and Flexible
New journals and regional markets can be added to a screening program within 2–3 weeks of request, and the platform scales across simultaneous multi-drug monitoring programs without proportional staffing increases. The SaaS delivery model ensures 24/7 access across global teams spanning multiple time zones and regulatory regions.
फायदे और नुकसान
✅ फायदे
- Time Efficiency — DrugCard customers report 50–70% reductions in time spent on literature screening compared to manual reading workflows, freeing pharmacovigilance specialists to redirect hours previously consumed by journal review toward higher-value activities such as signal detection, PSUR authoring, and risk management planning.
- High Accuracy — The platform achieves 99% keyword recognition accuracy in its screening pipeline, minimizing missed adverse event signals and reducing the false-negative risk that manual reviewer fatigue introduces into high-volume screening programs — particularly for journals processed in multiple non-English languages simultaneously.
- Cost-Effective — By replacing specialist reading hours with automated AI-driven screening, DrugCard eliminates the variable staffing cost that scales linearly with the number of markets and journals in a monitoring program, delivering predictable SaaS pricing regardless of the geographic scope of a drug's regulatory obligations.
- Improved Compliance — Every screening action, journal coverage decision, and adverse event flag is automatically logged with full timestamps and user attribution, producing a complete audit trail that meets FDA 21 CFR Part 11 requirements and is ready for submission as evidence during health authority inspections without additional documentation effort.
❌ नुकसान
- Initial Learning Curve — Configuring DrugCard for a specific drug safety monitoring program — including defining the correct journal set, keyword lists, and adverse event signal taxonomy — requires familiarity with GVP literature screening methodology. Teams new to pharmacovigilance-specific software may need a structured onboarding period to configure the platform correctly before achieving reliable screening coverage.
- Limited Customization — While DrugCard's standard configuration covers the majority of GVP-compliant local literature monitoring use cases, programs with highly specialized drug class requirements — such as advanced therapy medicinal products (ATMPs) or niche orphan diseases with sparse literature footprints — may require direct engagement with DrugCard's team to configure appropriate coverage parameters.
विशेषज्ञ की राय
For CROs and MAHs managing multi-region literature monitoring obligations, DrugCard reduces the per-drug compliance burden from specialist hours to automated screening cycles with audit-ready output — its proprietary OCR accuracy at poorly scanned journal content is the technical differentiator that regional manual screening cannot match. The primary limitation is that DrugCard handles monitoring and screening only; adverse event case processing requires a separate safety database integration, making it a component in a broader pharmacovigilance stack rather than a standalone solution.
अक्सर पूछे जाने वाले सवाल
Yes — DrugCard offers a free 2-week trial that allows pharmacovigilance teams to test the platform's literature screening capabilities before committing to a paid subscription. The trial includes access to the core screening pipeline with multilingual coverage. Contact the DrugCard team via drug-card.io to initiate a trial for your specific monitoring program.
DrugCard uses proprietary OCR technology specifically trained on pharmaceutical and medical literature formats, including the degraded scan quality common in regional journals from lower-resource markets. Standard commercial OCR tools fail on low-DPI or compressed scans; DrugCard's engine is optimized for these conditions, delivering reliable text extraction from documents that general-purpose OCR would misread or skip entirely.
No — DrugCard is a literature screening and monitoring platform, not an adverse event case management system. It identifies and flags potential adverse event signals in literature, but case processing, MedDRA coding, and E2B submission workflows require integration with a dedicated safety database such as Argus Safety or Oracle Empirica. DrugCard functions as a monitoring module within a broader pharmacovigilance stack.
DrugCard is compliant with GVP Module VI for literature screening, supports FDA 21 CFR Part 11-compliant electronic records and signatures, and provides a certificate of conformity for use in the EU, US, and CIS regulatory jurisdictions. Its infrastructure is hosted on ISO/IEC 27001:2013 and SOC 2 Type II certified environments, ensuring enterprise-grade data security for drug safety information.